Olanzapine versus Aprepitant in the triplet regimen for preventing highly emetogenic chemotherapy-induced nausea and vomiting: a double blind, non-inferiority, randomized phase 3 trial - Olanzapine versus Aprepitant in the triplet regimen for preventing highly emetogenic chemotherapy-induced nausea and vomiting: a double blind, randomized phase 3 trial (KEIOSC trial)

Department of Surgery, Keio University School of Medicine0 个研究点目标入组 130 人开始时间: 2018年9月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) nausea or vomiting in the 24 hours before enrollment 2) past history of severe cognitive compromise and central nervous system disease 3) treatment with another antipsychotic agent within 30 days before enrollment 4) concurrent abdominal radiotherapy with chemotherapy 5) chronic alcoholism 6) cardiac arrhythmia and uncontrolled congestive heart failure within the previous 6 months 7) a patient with a bowel obstruction 8) a patient with pregnancy or a patient at risk of becoming pregnant 9) a patient with contraindications to aprepitant, olanzapine, granisetron and dexamethasone

发起方

Department of Surgery, Keio University School of Medicine